Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer patients during the dose escalation phase

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.10.19
Views: 774

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

Prof Marwan Fakih speaks to ecancer at ESMO 2019 in Barcelona about the results from the phase I SPICE study, which investigated the combination of enadenotucirev plus nivolumab in metastatic tumours of epithelial origin.

He presents the latest results obtained from this study, in which the patients with metastatic colorectal cancer lived longer than expected and experienced a median overall survival of more than 12 months.

Prof Fakih believes there is more to be learned as prior studies have suggested enadenotucirev increases T-cell infiltration and may be synergistic to the action of some checkpoint inhibitors. However, biomarkers for this response are yet to be determined, along with the underlying mechanisms of synergy and resistance.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation